Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) – Equities research analysts at Capital One Financial lifted their Q1 2023 EPS estimates for Day One Biopharmaceuticals in a report released on Tuesday, March 7th. Capital One Financial analyst N. Quibria now anticipates that the company will earn ($0.58) per share for the quarter, up from their prior estimate of ($0.60). Capital One Financial has a "Overweight" rating and a $40.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($2.41) per share. Capital One Financial also issued estimates for Day One Biopharmaceuticals' Q2 2023 earnings at ($0.60) EPS, Q3 2023 earnings at ($0.63) EPS, Q4 2023 earnings at ($0.66) EPS, FY2023 earnings at ($2.47) EPS, Q1 2024 earnings at ($0.50) EPS, Q2 2024 earnings at ($0.52) EPS, Q3 2024 earnings at ($0.56) EPS, Q4 2024 earnings at ($0.59) EPS and FY2024 earnings at ($2.17) EPS.

A number of other research firms have also weighed in on DAWN. Oppenheimer began coverage on shares of Day One Biopharmaceuticals in a report on Thursday, February 2nd. They issued a "market perform" rating on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $48.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday. The Goldman Sachs Group raised their price target on shares of Day One Biopharmaceuticals from $45.00 to $62.00 and gave the company a "buy" rating in a report on Monday, January 9th. HC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday. Finally, Piper Sandler raised their price objective on shares of Day One Biopharmaceuticals from $40.00 to $45.00 and gave the company an "overweight" rating in a research report on Sunday, January 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $44.14.

Day One Biopharmaceuticals Price Performance

DAWN stock opened at $17.95 on Friday. The stock has a market capitalization of $1.32 billion, a PE ratio of -8.27 and a beta of -1.94. The company's 50-day moving average is $20.65 and its 200-day moving average is $20.92. Day One Biopharmaceuticals has a 1 year low of $5.44 and a 1 year high of $28.35.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, January 10th. The shares were sold at an average price of $22.86, for a total transaction of $228,600.00. Following the sale, the insider now owns 1,250,148 shares of the company's stock, valued at approximately $28,578,383.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Samuel C. Blackman sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $22.86, for a total value of $228,600.00. Following the transaction, the insider now owns 1,250,148 shares in the company, valued at $28,578,383.28. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Julie Papanek Grant sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $20.65, for a total transaction of $516,250.00. Following the transaction, the director now directly owns 380,000 shares of the company's stock, valued at $7,847,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 107,126 shares of company stock worth $2,243,406. 8.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Alliancebernstein L.P. lifted its position in Day One Biopharmaceuticals by 10.3% during the fourth quarter. Alliancebernstein L.P. now owns 41,900 shares of the company's stock valued at $902,000 after purchasing an additional 3,900 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in shares of Day One Biopharmaceuticals by 393.9% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 115,500 shares of the company's stock valued at $2,486,000 after purchasing an additional 92,113 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at about $663,000. Laurion Capital Management LP raised its holdings in shares of Day One Biopharmaceuticals by 5.4% in the 4th quarter. Laurion Capital Management LP now owns 15,000 shares of the company's stock valued at $323,000 after purchasing an additional 763 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at about $2,324,000. 86.08% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Company Profile

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Recommended Stories

• Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
• 2 Offshore Drilling Stocks Set to Extract Big Profits
• Three Staples Stocks With Double-Digit Upside Ahead
• Can Investors Trust Consumers to Lift American Outdoor Brands?
• How to Buy High Yielding Dividend Stocks
• Oracle Has Spoken: Shares Fall 5%

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.